Cargando…

Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants

SARS-CoV-2 poses an unprecedented threat to the world as the causative agent of the COVID-19 pandemic. Among a handful of therapeutics developed for the prevention and treatment of SARS-CoV-2 infection, ensitrelvir is the first noncovalent and nonpeptide oral inhibitor targeting the main protease (M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Mengmeng, Zeng, Xudong, Duan, Yinkai, Yang, Zinan, Ma, Yuanyuan, Yang, Haitao, Yang, Xiuna, Liu, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322880/ https://www.ncbi.nlm.nih.gov/pubmed/37407698 http://dx.doi.org/10.1038/s42003-023-05071-y

Ejemplares similares

The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2
por: Jin, Zhenming, et al.
Publicado: (2021)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
por: Noske, Gabriela Dias, et al.
Publicado: (2023)

Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2
por: Zhao, Yao, et al.
Publicado: (2022)

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally
por: Kawashima, Sho, et al.
Publicado: (2023)

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
por: Ip, Jonathan Daniel, et al.
Publicado: (2023)

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
por: Kuroda, Takayuki, et al.
Publicado: (2023)

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model
por: Fukao, Keita, et al.
Publicado: (2023)

Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2
por: Yang, Yujian, et al.
Publicado: (2023)

High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors
por: Zang, Yi, et al.
Publicado: (2022)

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
por: Dai, Wenhao, et al.
Publicado: (2020)

Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19
por: Cui, Wen, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2022)

Structure of SARS-CoV-2 main protease in the apo state
por: Zhou, Xuelan, et al.
Publicado: (2020)

Effect of chitooligosaccharide on the inhibition of SARS-CoV-2 main protease
por: Wang, Qian, et al.
Publicado: (2023)

Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
por: Amporndanai, Kangsa, et al.
Publicado: (2021)

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
por: Ullrich, Sven, et al.
Publicado: (2022)

Chlorhexidine and SARS-CoV-2 main protease: Molecular docking study
por: Grover, Vishakha, et al.
Publicado: (2022)

530. Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection
por: Ishibashi, Toru, et al.
Publicado: (2023)

Activation and maturation of SARS-CoV main protease
por: Xia, Bin, et al.
Publicado: (2011)

Screening of potential inhibitors targeting the main protease structure of SARS-CoV-2 via molecular docking
por: Yang, Xinbo, et al.
Publicado: (2022)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

Crystal structures of main protease (M(pro)) mutants of SARS-CoV-2 variants bound to PF-07304814
por: Jiang, Haihai, et al.
Publicado: (2023)

Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors
por: Cardoso, Wesley B., et al.
Publicado: (2021)

High-throughput screening and evaluation of repurposed drugs targeting the SARS-CoV-2 main protease
por: Li, Yan, et al.
Publicado: (2021)

Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease
por: Menéndez, Cintia A., et al.
Publicado: (2020)

Drug repurposing for SARS-CoV-2 main protease: Molecular docking and molecular dynamics investigations
por: Omer, Samia E., et al.
Publicado: (2022)

The SARS-CoV-2 main protease as drug target
por: Ullrich, Sven, et al.
Publicado: (2020)

Topological analysis of SARS CoV-2 main protease
por: Estrada, Ernesto
Publicado: (2020)

Potential SARS-CoV-2 main protease inhibitors
por: Banerjee, Riddhidev, et al.
Publicado: (2021)

Developing inhibitors of the SARS-CoV-2 main protease
por: Seitz, Christian, et al.
Publicado: (2022)

Allosteric Hotspots in the Main Protease of SARS-CoV-2
por: Strömich, Léonie, et al.
Publicado: (2022)

Allosteric inhibitors of the main protease of SARS-CoV-2
por: Samrat, Subodh Kumar, et al.
Publicado: (2022)

Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023)

Molecular docking and dynamics simulation of main protease of SARS-CoV-2 with naproxen derivative
por: K Hussein, Rageh, et al.
Publicado: (2023)

QSAR and molecular docking studies on designing potent inhibitors of SARS-CoVs main protease
por: Song, Fucheng, et al.
Publicado: (2023)

Search of Novel Small Molecule Inhibitors for the Main Protease of SARS-CoV-2
por: Zhang, Wenfa, et al.
Publicado: (2023)

Plant flavonoid inhibition of SARS-CoV-2 main protease and viral replication
por: Lin, Lin, et al.
Publicado: (2023)

The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
por: Pang, Xiaojing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i2454tqdsav4r6od9du2so465v